CARB-X IS FUNDING AFFINIVAX TO DEVELOP A NOVEL VACCINE TO PREVENT STAPHYLOCOCCUS AUREUS BACTERIAL INFECTIONS

  10 March 2021

CARB-X is funding Affinivax, a Cambridge, Massachusetts, USA, biotech, to develop a new vaccine that will prevent Staphylococcus aureus (S. aureus) bacterial infections, healthcare-associated infections that are a major health threat particularly to high-risk and older patients. No vaccine exists currently to prevent S. aureus infections, and there are limited treatment options, particularly with the spread of multidrug-resistant strains of the pathogen, often described as methicillin-resistant S. aureus (MRSA).

The CARB-X award is worth up to $3.5 million, and could provide up to $18.5 million more if the project successfully progresses through certain development milestones, subject to availability of funds. The funding will support optimization of Affinivax’s lead candidate to potentially advance toward submission of an investigational new drug (IND) application to the US Food and Drug Administration (FDA) and evaluation in clinical studies.

Further reading: CARB-X
Author(s): Jennifer Robinson
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 650 AMR professionals and students in 65 countries!

Register

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed